Health AI Register Logo
ProductsCompaniesNewsContact

Key Features

  • MRI image enhancement

General Information

Product name

AiMiFY

Subspeciality

Neuro

Modality

MRI

Disease targeted

Cerebritis, glioma, inflammation, lymphoma, meningioma, metastatic lesions, multiple sclerosis, neuritis, other tumor-related lesions (e.g., resection / radiation necrosis / suspected cyst / etc.), and other abnormalities.

Main task

Not specified

Technical Specifications

Population

Patiets from 7 to 86 years old. AiMIFY inherently doesn't cause harm to patients. However, gadolinium-based contrast agents are associated with contraindications, precautions, and warnings for certain subpopulations.

Patient population age

Adult, Elderly, Pediatric

Input

T1 weighted pre and post contrast images, gadolinium-based contrast agents, 2D and 3D sequences, axial/coronal/sagittal orientations, all major vendors, field strength: 0.3T, 1.5T, 3.0T, protocols: BRAVO, FSE, MPRAGE, T1, T1 Flair

Input format

DICOM

Output

Contrast enhanced brain MR images

Output format

DICOM

Integration

Integration CIS (Clinical Information System), Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform

Deployment

Cloud-based, Locally on dedicated hardware, Locally virtualized (virtual machine, docker)

Trigger for analysis

Automatically, Image upload, On demand, Right after the image acquisition, Triggered by a user through e.g. a button click

Processing time

1 - 10 minutes

Regulatory Information

CE Certification

Pathway:

MDR

Class:

Class IIa

Not verified by Health AI Register
FDA Certification

Pathway:

510(k) cleared

Class:

Class II

Verified by Health AI Register

Other certifications

Not specified

Market Presence

On market since

08-2024

AI Platforms

Not specified

Resellers

Not specified

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Not specified

Based on

Not specified

Evidence & Research

No research papers or evidence available for this product.

Source: vendor | First published: Jul 29, 2025 | Last updated: Jul 29, 2025